Evolution of the Average Target: Quest Diagnostics Incorporated

Evolution of the Average Target - Quest Diagnostics Incorporated

Evolution of the Target Price: Quest Diagnostics Incorporated

Evolution of the Target Price - Quest Diagnostics Incorporated

Changes in Analyst Recommendations: Quest Diagnostics Incorporated

c78314632167560e1b05b300e0d2df.PWRGbgMTPeqelpOlmwGlvIiRbCGYsVAQ5__Tnnc0Y9I.DgErOWl1b5vc2qXq9UrT1OflOxX29T91o72J7i5FIIEJKzEbQCBenfvXpw~faa8b575ae694925a6c32f7d22096e93
01:21pm Barclays Adjusts Price Target on Quest Diagnostics to $260 From $250, Keeps Overweight Rating MT
12:38pm Evercore ISI Adjusts Price Target on Quest Diagnostics to $235 From $240, Keeps In Line Rating MT
09-22 Baird Adjusts Price Target on Quest Diagnostics to $260 From $255, Maintains Neutral Rating MT
09-21 Truist Raises Price Target on Quest Diagnostics to $260 From $250, Keeps Hold Rating MT
09-08 UBS Adjusts Quest Diagnostics Price Target to $245 From $232, Maintains Neutral Rating MT
07-30 Argus Research Adjusts Quest Diagnostics Price Target to $260 From $225, Maintains Buy Rating MT
07-28 JPMorgan Adjusts Price Target on Quest Diagnostics to $250 From $220, Maintains Neutral Rating MT
07-27 Rothschild & Co Redburn Adjusts Quest Diagnostics Price Target to $251 From $233, Maintains Buy Rating MT
07-24 UBS Adjusts Price Target on Quest Diagnostics to $232 From $220, Maintains Neutral Rating MT
07-24 Baird Adjusts Quest Diagnostics Price Target to $255 From $236, Maintains Neutral Rating MT
07-24 Barclays Raises Quest Diagnostics Price Target to $250 From $230, Maintains Overweight Rating MT
07-24 Mizuho Securities Adjusts Quest Diagnostics Price Target to $260 From $235, Maintains Outperform Rating MT
07-24 Deutsche Bank Adjusts Quest Diagnostics Price Target to $232 From $205, Maintains Hold Rating MT
07-24 Truist Raises Price Target on Quest Diagnostics to $250 From $225, Keeps Hold Rating MT
07-24 Morgan Stanley Adjusts PT on Quest Diagnostics to $260 From $226, Maintains Overweight Rating MT
07-23 Evercore ISI Cuts Quest Diagnostics Price Target to $240 From $225 MT
07-15 Leerink Partners Adjusts Quest Diagnostics Price Target to $244 From $240, Maintains Outperform Rating MT
05-18 Baird Adjusts Price Target on Quest Diagnostics to $232 From $229, Maintains Neutral Rating MT
04-27 Rothschild & Co Redburn Adjusts Price Target on Quest Diagnostics to $233 From $224, Maintains Buy Rating MT
04-22 UBS Adjusts Quest Diagnostics Price Target to $220 From $210, Maintains Neutral Rating MT
04-22 Truist Lifts Price Target on Quest Diagnostics to $225 From $220, Keeps Hold Rating MT
04-22 Evercore ISI Adjusts Price Target on Quest Diagnostics to $225 From $210, Maintains In Line Rating MT
04-22 Jefferies Adjusts Price Target on Quest Diagnostics to $225 From $220, Maintains Buy Rating MT
04-22 Barclays Adjusts Price Target on Quest Diagnostics to $230 From $225, Maintains Overweight Rating MT
04-22 Baird Adjusts Price Target on Quest Diagnostics to $229 From $224, Maintains Neutral Rating MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+6.68%
+33.5%
+4.44%
-14%
+26.72%
+11.51%
+18.93%
+9.7%
+31.86%
+11.68%
Average +14.10%
Weighted average by Cap. +13.82%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
232.22USD
Average target price
247.40USD
Spread / Average Target
+6.54%
High Price Target
265.00USD
Spread / Highest target
+14.12%
Low Price Target
204.00USD
Spread / Lowest Target
-12.15%

Analyst Consensus Detail

Analyst consensus - Quest Diagnostics Incorporated

Consensus revision (last 18 months)

Consensus revision (last 18 months) - Quest Diagnostics Incorporated
Trader
Investor
Global
Quality
ESG MSCI
AA
Ratings Surperformance© - Quest Diagnostics Incorporated
  1. Stock Market
  2. Stocks
  3. DGX Stock
  4. Consensus Quest Diagnostics Incorporated